Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication May 18, 2018
- Accepted for publication January 3, 2019
- Published online July 1, 2019.
Article Versions
- previous version (February 7, 2019 - 09:19).
- previous version (February 22, 2019 - 13:06).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2019 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.
Author Information
- C. Willemien Menke-van der Houven van Oordt*,1,
- Adam McGeoch*,2,
- Mats Bergstrom3,
- Iain McSherry4,
- Deborah A. Smith5,
- Matthew Cleveland6,
- Wasfi Al-Azzam7,
- Liangfu Chen8,
- Henk Verheul1,
- Otto S. Hoekstra9,
- Danielle J. Vugts9,
- Immanuel Freedman10,
- Marc Huisman9,
- Chris Matheny11,
- Guus van Dongen9 and
- Sean Zhang12
- 1Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands
- 2Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
- 3OMID Molecular Imaging Consultancy, Uppsala, Sweden
- 4Clinical Pharmacology, Science, and Study Operations, GlaxoSmithKline, Uxbridge, United Kingdom
- 5Clin Pharm Advantage, LLC, Durham, North Carolina
- 6Bioimaging, Platform Technology and Science, GlaxoSmithKline, Stevenage, United Kingdom
- 7Biopharm Product Development and Supply, GlaxoSmithKline, King of Prussia, Pennsylvania
- 8Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania
- 9Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- 10Freedman Patent, Harleysville, Pennsylvania
- 11Oncology R&D, GlaxoSmithKline, King of Prussia, Pennsylvania; and
- 12Hengrui Therapeutics, Inc., Princeton, New Jersey
- For correspondence contact: C. Willemien Menke-van der Houven van Oordt, VU University Medical Centre, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. E-mail: c.menke{at}vumc.nl
↵* Contributed equally to this work.
